cathepsin
famili
proteas
high
therapeut
valu
sinc
present
human
parasit
like
mani
proteas
cathepsin
activ
low
ph
provid
lysosom
activ
mainli
restrict
organel
except
cathepsin
k
famili
protein
classifi
distinguish
structur
catalyt
mechan
protein
cleav
cathepsin
b
c
f
h
k
l
v
w
x
cystein
proteas
cathepsin
e
aspartyl
proteas
cathepsin
g
serin
proteas
cathepsin
vital
role
mammalian
cellular
protein
turnov
among
mammalian
cathepsin
cystein
proteas
ubiquit
express
cathepsin
b
h
x
c
l
therefor
assum
housekeep
enzym
remain
five
select
express
welldefin
tissu
cell
type
cathepsin
k
osteoclast
v
thymu
antigenpres
cell
f
macrophag
w
nk
ctl
cell
last
decad
proteolyt
activ
cathepsin
relat
mani
metabol
process
also
involv
diseas
evolut
immunolog
respons
interest
cathepsin
therapeut
target
mani
diseas
also
increas
exampl
activ
cathepsin
relat
cancer
cerebrovascular
accid
alzheim
diseas
arthriti
chronic
obstruct
pulmonari
diseas
glaucoma
among
other
also
report
virus
evolv
use
cathepsin
favor
infect
cell
like
ebola
viru
sar
coronaviru
order
find
drug
candid
scientist
usual
get
inspir
natur
product
isol
plant
fungi
bacteria
one
first
isol
natur
product
cathepsin
inhibitor
leupeptin
fig
identifi
strain
streptomyc
exfoliatu
leupeptin
peptidyl
aldehyd
exhibit
inhibitori
activ
cathepsin
b
ic
nm
respect
leupeptin
follow
small
peptid
aldehyd
chymostatin
ic
valu
cathepsin
b
respect
antipain
proteas
inhibitor
isol
actinomycet
exhibit
vitro
inhibitori
activ
cathepsin
ic
cathepsin
b
respect
microbi
alkalin
proteas
inhibitor
mapi
unfortun
aldehyd
inhibitor
requir
nucleophil
attack
cystein
proteas
make
target
nucleophil
attack
proteas
serin
proteas
result
nonselect
inhibit
inhibit
cathepsin
b
moreov
crystal
structur
human
cathepsin
bovin
cathepsin
complex
show
nearli
bind
mode
sequenc
n
subsit
remark
differ
bind
mode
papainfamili
cystein
proteas
fig
uniqu
structur
featur
cathepsin
b
ie
presenc
cathepsin
b
occlud
loop
near
activ
site
cathepsin
b
miss
papainfamili
proteas
creat
situat
inform
given
xray
crystal
structur
sar
studi
allow
research
ration
design
new
drug
candid
enhanc
specif
andor
potenc
ishida
group
thought
therapeut
point
view
would
desir
develop
noncovalenttyp
lowmolecularweight
version
analogu
cathepsin
b
epoxyfre
version
known
inhibitor
test
due
lack
epoxi
ring
led
consider
loss
inhibitori
activ
strategi
follow
design
compound
abl
block
n
n
subsit
simultan
thu
compound
construct
manual
model
build
base
xray
atom
coordin
cathepsin
complex
possibl
bind
mode
energet
stabil
candid
activ
site
cathepsin
b
simul
molecular
dynam
md
calcul
among
synthet
compound
includ
peptid
structur
fig
exhibit
potent
inhibitori
activ
initi
ic
nm
md
simul
suggest
interact
cathepsin
b
conserv
fig
one
strategi
synthet
new
drug
candid
lead
compound
modif
chemic
reactiv
portion
inhibitor
ie
epoxid
ring
similar
chemic
structur
epoxid
aziridin
also
threememb
ring
atom
nitrogen
instead
oxygen
chemic
analogu
first
synthes
test
cystein
proteas
martichonok
et
al
publish
aziridin
analogu
compar
bioactiv
differ
cystein
proteas
version
previous
synthet
epoxi
analogu
one
interest
conclus
public
bring
fact
ph
depend
inactiv
enzym
quit
differ
aziridin
inhibitor
compar
epoxid
inhibitor
effect
explain
aziridin
ring
potenti
easili
proton
nitrogen
atom
addit
aziridin
shown
reactiv
low
ph
contrast
proton
like
occur
ph
rang
cystein
proteas
activ
optim
ph
lysosom
activ
presenc
aziridin
ring
within
carboxyl
group
alpha
posit
rare
moieti
natur
product
year
nakao
et
al
encount
marin
blue
spong
relat
theonella
mirabili
collect
cruis
amami
tokara
island
japan
extract
spong
show
varieti
bioactiv
antifung
proteas
inhibitori
extract
mani
compound
isol
among
miraziridin
fig
tetrapeptid
molecul
alphacarboxyl
aziridin
acid
moieti
also
elucid
structur
test
inhibitori
activ
cathepsin
b
ic
valu
later
compound
identifi
red
sea
spong
theonella
swinhoei
schaschk
describ
studi
miraziridin
notic
natur
tetrapeptid
seem
uniqu
unifi
within
one
molecul
three
inhibitori
element
acid
acid
statin
e
acid
vinylog
arginin
former
one
constitut
known
cystein
aspartyl
proteas
moieti
inhibitor
latter
one
might
inhibit
trypsinlik
serin
proteas
order
investig
hypothesi
compound
contain
three
mention
moieti
miraziridin
synthes
inhibitori
properti
assess
therefor
schaschk
decid
develop
synthet
strategi
obtain
compound
laboratori
scale
retrosynthet
analysi
propos
fig
involv
two
key
step
introduct
fragment
late
stage
synthesi
final
deprotect
step
sinc
aziridin
moieti
sensit
nucleophil
ring
open
select
proper
protect
group
allow
select
unmask
nterminu
also
protectingdeprotect
friendli
condit
doubl
bond
present
vinylog
arginin
thu
bpocboc
combin
fragment
respect
select
start
miraziridin
synthet
overal
yield
synthet
miraziridin
test
trypsin
serin
proteas
cathepsin
b
cathepsin
l
cystein
proteas
well
pepsin
aspartyl
proteas
obtain
chainunprotect
vargoet
late
stage
backbon
construct
make
possibl
adopt
conveni
solidphas
procedur
fragment
prepar
order
estim
major
effect
miraziridin
cathepsin
b
reactiv
site
three
truncat
analog
fig
also
synthes
test
inhibitori
activ
synthet
miraziridin
analogu
cathepsin
b
ic
valu
synthet
miraziridin
similar
report
natur
product
compar
ic
k
valu
ic
k
ic
k
expect
inhibitori
activ
attribut
mainli
aziridin
site
miraziridin
though
vinylog
arginin
site
rather
weak
effect
compar
aziridin
site
inhibitori
activ
acleustaabuvargoh
time
hleustaabuoh
also
marin
spong
mirabili
cathepsin
b
inhibitor
tokaramid
fig
isol
structur
elucid
fusetani
et
al
name
compound
coin
name
site
collect
tokara
archipelago
japan
character
compound
fabm
show
three
main
ion
peak
mz
correspond
h
h
h
h
meoh
suggest
facil
format
hemiacet
water
meoh
interpret
nmr
data
confirm
presenc
methyl
hemiacet
cd
oh
nmr
data
led
structur
subunit
extract
conclus
tokaramid
exist
equilibrium
mixtur
aldehyd
hemiacet
cyclic
carbinolamin
ic
cathepsin
b
measur
give
valu
inhibit
ngml
compar
gave
valu
ngml
recent
konno
group
report
first
total
synthesi
tokaramid
miraziridin
develop
solidphas
methodolog
synthesi
sinc
argu
solid
phase
use
way
obtain
librari
similar
compound
howev
first
attempt
obtain
trace
tokaramid
cyclic
carbinolamin
form
found
one
major
byproduct
came
side
reaction
deprotect
step
acid
condit
favor
dehydr
cyclic
tokaramid
fig
identifi
annoy
byproduct
choos
altern
path
protectiondeprotect
step
condit
final
achiev
total
synthesi
tokaramid
cycliz
hemiamin
structur
overal
yield
spong
alway
known
sourc
natur
product
recent
marin
cyanobacteria
emerg
import
sourc
drug
discoveri
marin
cyanobacteria
except
rich
biolog
activ
compound
offer
great
varieti
metabolit
peptid
terpen
sugar
commonli
decor
halogen
atom
methyl
group
function
group
interest
oxid
state
one
compound
gallinamid
fig
howev
compound
majorli
studi
activ
malaria
recent
studi
found
gallinamid
offer
inhibitori
activ
human
cathepsin
isol
bioactiv
compound
via
hplcm
perform
seri
nmr
experi
elucid
structur
absolut
configur
stereocent
assign
subsequ
degrad
derivat
howev
abl
determin
absolut
configur
carbon
atom
n
ndimethyl
isoleucin
residu
curious
year
anoth
natur
product
structur
isol
symploca
cyanobacteria
report
literatur
name
symplostatin
paper
configur
stereocent
assign
two
stereocent
n
ndimethyl
isoleucin
residu
nevertheless
ensur
symplostatin
differ
compound
gallinamid
probabl
diastereom
nmr
spectrum
compound
slightli
differ
doubt
clear
total
synthesi
compound
possibl
diastereom
report
conroy
et
al
present
first
synthesi
symplostatin
possibl
diastereom
order
compar
synthet
compound
natur
sourc
envisag
ntermin
diastereom
could
synthes
final
fragment
condens
correspond
ntermin
isomer
fragment
key
ctermin
imid
fragment
synthesi
isomer
depsipeptid
fragment
could
achiev
esterif
suitabl
protect
isocapro
acid
unit
correspond
isomer
isoleucin
build
block
access
fragment
propos
converg
assembl
three
suitabl
protect
build
block
pyrrolinon
unit
bocprotect
e
penteno
acid
boclleucineoh
fig
four
compound
synthet
overal
yield
h
c
nmr
spectral
data
four
compound
show
larg
degre
similar
subtl
differ
enough
discern
one
anoth
comparison
spectra
synthet
gallinamid
symplostatin
show
natur
compound
ident
molecul
absolut
configur
mention
earlier
gallinamid
studi
antimalari
agent
recent
product
shown
inhibitori
activ
human
cystein
cathepsin
l
also
high
select
front
human
cystein
proteas
cathepsin
v
b
publish
work
miller
et
al
recent
studi
reveal
cathepsin
l
present
mani
tumor
perform
import
role
bone
metastasi
work
miller
et
al
first
demonstr
gallinamid
block
bind
activitybas
probe
abp
biotinlabel
deriv
potent
cystein
cathepsin
inhibitor
unlik
experi
measur
enzym
inhibit
abp
studi
investig
abil
compound
compet
potent
activ
sitedirect
probe
measur
ic
shown
timedepend
preincub
doserespons
experi
immedi
mix
enzym
substrat
inhibitor
gallinamid
ic
nm
observ
follow
preincub
enzym
inhibitor
min
prior
addit
substrat
gallinamid
display
increas
potenc
ic
nm
timedepend
inhibit
hallmark
slowbind
inhibitor
select
also
test
gallinamid
inhibitori
activ
test
homolog
human
cystein
proteas
cathepsin
v
cathepsin
b
also
obtain
ic
valu
without
preincub
inhibitor
enzym
describ
cathepsin
l
interestingli
gallinamid
display
increas
potenc
cathepsin
l
rel
cathepsin
v
without
preincub
increas
allow
preincub
min
select
even
bigger
cathepsin
l
compar
cathepsin
b
show
increas
ic
follow
min
preincub
experi
show
also
gallinamid
inhibit
irrevers
cathepsin
l
hypothet
via
michael
addit
reactiv
gallinamid
enamid
comput
studi
also
perform
find
stabl
enzymeinhibitor
complex
order
gather
inform
noncoval
interact
bring
inform
ration
develop
bioactiv
analogu
gallinamid
anoth
prolif
sourc
bioactiv
secondari
metabolit
come
lyngbya
cyanobacteria
genu
luesch
group
investig
lyngbya
confervoid
marin
cyanobacterium
florida
water
report
isol
new
cytotox
depsipeptid
grassypeptolid
fig
ring
cyclic
depsipeptid
contain
interest
moieti
acid
aba
acid
maba
thiazolin
ring
unusu
high
number
damino
acid
nmr
xray
techniqu
use
elucid
structur
compound
cytotox
activ
grassypeptolid
evalu
four
cell
line
deriv
human
osteosarcoma
cervic
carcinoma
hela
colorect
adenocarcinoma
neuroblastoma
ic
valu
respect
denot
moder
broadspectrum
activ
previous
report
thiazolin
lissoclinamid
cytotoxicrel
cyclic
peptid
import
biolog
activ
two
year
later
luesch
group
report
isol
chemic
structur
elucid
two
new
grassypeptolid
name
b
c
l
confervoid
chemic
structur
elucid
use
nmr
xray
ms
experi
observ
differ
three
grassypeptolid
resid
two
residu
fig
moreov
c
found
epim
question
worri
research
whether
intact
molecul
interconvert
preced
similar
natur
product
exampl
synthet
diastereom
lissoclinamid
show
convers
natur
isom
presenc
pyridin
cdcl
although
revers
convers
observ
use
condit
luesch
group
abl
convert
intact
grassypeptolid
c
grassypeptolid
vice
versa
reduc
tendenc
baseinduc
interconvers
may
reflect
less
overal
strain
macrocycl
grassypeptolid
c
wherea
lissoclinamid
compound
b
c
test
alongsid
two
cell
line
colorect
adenocarcinoma
hela
cervic
carcinoma
surprisingli
c
time
potent
potent
b
presum
due
differ
conform
suggest
region
around
meph
crucial
cytotox
interest
c
activ
seri
recov
minor
compon
cyanobacteri
extract
could
indic
requir
activ
epimer
possibl
strategi
selfresist
produc
organ
total
synthesi
grassypeptolid
confirm
structur
order
investig
path
activ
inhibitor
follow
studi
perform
kwan
et
al
prompt
find
similar
cyclic
peptid
kwan
et
al
investig
metal
bind
grassypeptolid
c
found
bind
cu
zn
ion
metal
known
play
crucial
role
mechan
certain
enzym
matrix
metalloproteas
mmp
cu
znsuperoxid
dismutas
exampl
work
decid
screen
grassypeptolid
abund
natur
product
seri
repres
panel
proteas
howev
except
weak
effect
observ
inhibit
metalloproteas
panel
instead
strongest
hit
cystein
proteas
cathepsin
l
serin
proteas
activ
protein
c
apc
ec
dipeptidyl
peptidas
ec
inhibit
residu
activ
respect
rel
solvent
control
screen
concentr
anoth
kind
compound
cytotox
activ
describ
inhibitor
cathepsin
l
cystein
cathepsin
cyclohexenyl
chalcon
deriv
panduratin
nicolaioidesin
c
fig
panduratin
relat
nicolaioidesin
c
found
red
rhizom
varieti
boesenbergia
pandurata
fingerroot
isol
panduratin
shown
consider
cytotox
effect
human
androgenindepend
prostat
cancer
cell
apoptosi
littl
effect
normal
human
prostat
epitheli
cell
know
cathepsin
involv
cancer
process
result
open
new
research
line
order
relat
cytotox
activ
cyclohexenyl
chalcon
inhibit
cathepsin
panduratin
nicolaioidesin
c
found
racem
mixtur
natur
addit
total
synthes
compound
report
mixtur
enantiom
via
dielsald
cyclohexenyl
format
porco
et
al
majumdar
et
al
use
report
synthes
porco
obtain
enough
amount
compound
order
perform
seri
experi
relat
bioactiv
cyclohexenyl
chalcon
cathepsin
inhibit
compar
result
activ
natur
extract
cytotox
assay
racem
panduratin
nicolaioidesin
c
human
androgenindepend
prostat
cancer
cell
show
estim
ic
panduratin
nicolaioidesin
c
consist
activ
natur
extract
synthet
panduratin
subject
proteas
profil
experi
result
demonstr
panduratin
possess
substanti
inhibitori
activ
cathepsin
g
h
k
l
v
x
synthet
panduratin
enantiom
also
test
abil
inhibit
select
cathepsin
ic
valu
similar
determin
racem
mixtur
nicolaioidesin
c
subject
full
proteas
profil
protocol
select
assay
demonstr
anticathepsin
k
activ
ic
similar
observ
panduratin
importantli
proteas
profil
assay
panduratin
show
activ
class
proteas
includ
matrix
metalloproteas
caspas
papain
base
proteas
profil
result
signific
cathepsin
l
prostat
cancer
majumdar
et
al
also
test
synthet
racem
cyclohexenyl
chalcon
compound
cellfre
human
cathepsin
l
enzym
assay
use
nonselect
proteas
inhibitor
posit
control
presenc
panduratin
nicolaioidesin
c
result
significantli
reduc
human
cathepsin
l
enzym
activ
calcul
ic
respect
sever
compound
isol
divers
plant
garcinia
genu
shown
mani
interest
biolog
activ
polycycl
polyprenyl
acylphloroglucinol
ppap
isol
plant
gain
interest
due
mani
biolog
properti
anticanc
antivir
anticoncept
antiinflammatori
martin
et
al
publish
studi
describ
vitro
inhibitori
activ
three
natur
product
isol
garcinia
brasiliensi
differ
cystein
serin
proteas
includ
cathepsin
b
cathepsin
g
respect
name
guttiferon
garciniaphenon
fig
natur
polyprenyl
benzophenon
isol
ethanol
hexan
extract
g
brasiliensi
dri
powder
seed
fruit
previous
report
test
potenti
inhibit
papain
trypsin
cathepsin
b
g
spectrofluorometr
measur
refer
cathepsin
leupeptin
chymostatin
use
refer
inhibitor
trial
cathepsin
b
cathepsin
g
respect
one
benzophenon
deriv
guttiferon
avidli
inhibit
assay
enzym
differ
degre
select
proteas
import
highlight
ic
valu
cathepsin
g
almost
obtain
classic
inhibitor
serin
proteas
chymostatin
cathepsin
b
guttiferon
also
activ
compound
seri
howev
case
activ
lower
control
compound
leupeptin
two
natur
product
gave
lower
inhibit
valu
ic
valu
cathepsin
b
cathepsin
g
respect
garciniaphenon
offer
ic
valu
result
one
conclus
martin
et
al
report
activ
relat
amount
prenyl
group
molecul
sinc
activ
lower
compound
less
number
prenyl
group
sar
studi
also
perform
guttiferon
flexibl
dock
simul
state
presenc
bicycl
nonanetrion
substitut
phenyl
group
ketoenol
tautomer
form
bridg
carbon
hydroxyl
enhanc
enzymat
inhibitori
activ
likewis
biolog
effect
serin
cystein
proteas
improv
accord
number
prenyl
group
attach
diphenylmethanon
moieti
coplanar
bridg
hydroxylcarbonyl
group
research
perform
murata
et
al
link
activ
cathepsin
b
g
garciniaphenon
antiprolif
effect
variou
cancer
cell
better
result
observ
molecul
prenyl
group
explan
case
increas
hydrophob
thu
capac
penetr
cell
also
increas
biber
et
al
publish
first
total
synthesi
structur
analogu
natur
chemistri
accord
biolog
properti
relat
structur
rigid
bicycl
framework
lipophil
side
chain
hydrophil
trion
moieti
affect
bioactiv
retrosynthet
analysi
describ
clear
separ
framework
bicyclo
nonanetrion
core
construct
later
decor
introduct
correspond
substitu
strict
realiz
concept
would
allow
varieti
substitut
pattern
without
chang
entir
synthet
strategi
offer
chanc
futur
bioactivitydirect
synthesi
defin
ppap
librari
natur
compound
obtain
procedur
overal
chemic
yield
order
find
drug
candid
cancer
therapi
among
divers
natur
product
target
cathepsin
proteas
cancer
therapi
jedinak
et
al
conduct
research
natur
product
differ
plant
use
tradit
slovakian
medicin
test
cathepsin
b
urokinas
thrombin
trypsin
collect
natur
product
includ
seven
alkaloid
seven
flavonoid
two
triterpen
natur
flavonoid
quercetin
use
standard
test
proteas
among
test
compound
triterpen
inhibit
proteas
scale
alkaloid
bare
effect
proteas
ic
mm
flavonoid
moder
inhibit
urokinas
mani
inhibit
cathepsin
b
compound
major
activ
triterpen
acid
fig
inhibit
cathepsin
b
ic
similar
standard
ic
effect
acid
inhibit
vitro
cell
growth
larg
list
cancer
cell
line
includ
mous
melanoma
cell
evalu
vivo
daili
dose
mgkg
abil
inhibit
lung
colon
mortal
bodi
weight
chang
observ
chosen
dose
interest
fact
macroscop
appear
lung
untreat
treat
mice
clearli
show
ursol
acid
dose
mgkg
reduc
number
lung
metastas
effect
lower
higher
dose
unfortun
fact
explain
along
mechan
ursol
acid
action
investig
recent
studi
inhibitori
activ
ursol
acid
also
evalu
cathepsin
l
similar
natur
product
synthet
analogu
also
test
result
moder
ic
ursol
acid
improv
synthet
analogu
hydroxyl
group
chang
oxim
extra
methyl
group
ad
fig
anoth
natur
compound
gave
good
inhibitori
valu
cathepsin
l
schinol
also
improv
oxim
function
group
introduc
fig
anoth
public
report
activ
punica
granatum
extract
cathepsin
aspart
proteas
isol
bioactiv
compound
piperin
ursol
acid
crude
extract
differ
solvent
test
obtain
best
result
chloroform
extract
ic
isol
piperin
ic
ursol
acid
ic
semisynthet
analogu
also
test
slight
improv
inhibit
valu
flavonoid
class
plant
fungal
secondari
metabolit
chemic
structur
consist
two
phenyl
ring
b
heterocycl
ring
c
fig
plant
divers
import
sourc
natur
product
cerrado
biom
cover
brazil
land
surfac
rich
nonstudi
medicin
plant
ramalho
et
al
test
bioactiv
human
cathepsin
b
cathepsin
l
solvent
extract
seven
cerrado
plant
order
find
new
lead
compound
cancer
therapi
research
among
evalu
extract
ethanol
extract
myrcia
lingua
leav
major
inhibitori
activ
cathepsin
extract
select
continu
bioactivityguid
fraction
compound
fig
identifi
inhibitor
inhibitori
activ
test
individu
cathepsin
b
l
tabl
obtain
result
reveal
presenc
hydroxyl
group
ring
b
import
cathepsin
b
inhibit
comparison
activ
flavonoid
show
presenc
hydroxyl
group
ring
c
might
contribut
inhibitori
activ
replac
hydroxyl
group
r
hydrogen
substitu
caus
decreas
potenc
inhibit
cathepsin
b
analysi
enzym
inhibit
deriv
demonstr
import
doubl
bond
keton
group
compound
inhibit
cathepsin
b
l
also
observ
inhibit
cathepsin
b
complet
lost
replac
hydroxyl
group
methoxyl
substitu
ring
b
observ
entri
tabl
insight
demonstr
import
hydroxyl
group
ring
b
flavonoid
select
determin
type
inhibit
cathepsin
b
compound
show
uncompetit
inhibit
k
respect
ie
inhibitor
inhibit
enzymesubstr
complex
interact
free
enzym
leishmaniasi
tropic
diseas
caus
parasit
leishmania
transmit
mammalian
host
bite
sandfli
differ
speci
parasit
lead
cutan
leishmaniasi
mucocutan
leishmaniasi
viscer
leishmaniasi
studi
demonstr
cathepsin
l
b
leishmania
mexicana
repres
determin
key
virul
leishmania
infect
recent
publish
work
de
sousa
et
al
test
vitro
activ
flavonoid
triterpen
isol
plant
recombin
cathepsin
llike
l
mexicana
isoform
without
ctermin
extens
use
target
search
new
leishmanicid
compound
select
natur
product
studi
biflavonoid
agathisflavon
isol
leav
ouratea
nigroviolacea
tetrahydrorobustaflavon
isol
fruit
schinu
terebenthifoliu
ursol
acid
analogu
acid
isol
vochysia
thyrsoidea
commerci
avail
flavonoid
quercetin
fig
compound
subject
proteas
inhibit
assay
human
cathepsin
l
b
l
mexicana
cathepsin
llike
proteas
agathisflavon
gave
highest
inhibitori
activ
proteas
ic
follow
tetrahydrorobustaflavon
ic
acid
ic
quercetin
present
moder
inhibit
ic
howev
acid
show
signific
select
compar
inhibitori
activ
human
cathepsin
l
constrast
inhibitori
activ
higher
compar
human
cathepsin
l
rest
compound
ratio
reduc
higher
compar
human
cathepsin
l
kinet
studi
inhibitori
activ
also
perform
compound
except
quercetin
experi
show
partial
noncompetit
inhibit
agathisflavon
acid
uncompetit
inhibit
tetrahydrorobustaflavon
conclus
author
highlight
compound
could
investig
complement
current
drug
order
afford
new
pharmaceut
possibl
leishmaniasi
cathepsin
v
identifi
lysosom
cystein
proteas
specif
express
thymu
testi
corneal
epithelium
enzym
consid
potenti
diagnost
marker
colon
tumor
express
colorect
breast
carcinoma
normal
colon
mammari
tissu
thu
may
becom
valuabl
drug
target
oncolog
severino
et
al
present
first
exampl
use
natur
product
revers
competit
inhibitor
cathepsin
v
literatur
describ
biolog
evalu
type
inhibit
studi
seri
acridon
alkaloid
potent
inhibitor
cathepsin
v
molecular
model
preliminari
sar
studi
also
perform
investig
molecular
basi
underli
bind
affin
inhibitori
potenc
seri
natur
occur
compound
total
acridon
alkaloid
isol
methanol
extract
stem
bark
swinglea
glutinosa
test
recombin
human
cathepsin
v
tabl
seen
tabl
acridon
potent
inhibitor
ic
valu
compound
use
repres
inhibitor
cathepsin
v
comput
studi
seen
inhibitor
bind
central
region
cathepsin
v
substratebind
site
close
catalyt
residu
inhibitor
interact
enzym
set
four
hydrogen
bond
substitu
posit
pocket
hydrogen
bond
donor
mainchain
carbonyl
group
oxygen
atom
substitu
accept
hydrogen
bond
nh
side
chain
substitu
bind
pocket
act
hydrogen
bond
donor
mainchain
carbonyl
group
group
bind
pocket
accept
hydrogen
bond
nh
mainchain
addit
polar
contact
nonpolar
interact
contribut
orient
cathepsin
v
bind
site
conclus
sar
comput
studi
highlight
acridon
lead
compound
design
synthet
competit
inhibitor
cathepsin
v
report
recent
research
group
cathepsin
e
relat
aspartyl
proteas
kwan
et
al
describ
isol
structur
determin
biolog
evalu
three
linear
modifi
peptid
grassystatin
ac
fig
cyanobacteria
l
confervoid
three
contain
statin
unit
first
describ
broadspectrum
natur
aspart
proteas
inhibitor
pepstatin
test
aspart
proteas
inhibitori
activ
screen
compound
grassystatin
divers
proteas
found
select
inhibit
aspart
proteas
cathepsin
e
moreov
three
grassystatin
abl
discrimin
two
enzym
pepstatin
ic
valu
report
cathepsin
k
cystein
proteas
involv
osteoclastmedi
bone
resorpt
identifi
major
drug
target
treatment
osteoporosi
numer
potent
inhibitor
cathepsin
k
alreadi
identifi
natur
sourc
includ
epoxid
inhibitor
well
variou
small
peptidebas
aldehyd
natur
product
origin
leupeptin
chymostatin
antipain
alphamapi
mention
compound
togeth
pepstatin
potent
cathepsin
k
inhibitor
antipain
gave
k
nm
cathepsin
k
howev
select
enough
inhibit
one
proteas
instead
inhibit
whole
array
cystein
serin
proteas
render
inhibitor
toxic
therapeut
use
two
antipain
analogu
recent
isol
strain
streptomyc
collect
rainforest
british
columbia
display
inhibit
activ
cathepsin
k
lichostatin
fig
tripeptid
aldehyd
serileargh
agmatin
attach
urea
linkag
group
ser
agmatin
decarboxyl
arginin
lichostatin
first
exampl
natur
product
isol
complex
mixtur
cocrystal
biolog
target
second
compound
name
result
dehydr
cycloarginin
antipain
compound
cathepsin
k
inhibitor
display
valu
k
nm
natur
product
prove
use
therapeut
agent
toward
treatment
osteoporosi
reveal
new
insight
substrat
specif
cathepsin
k
aid
design
new
select
inhibitor
odanacatib
fig
select
inhibitor
cathepsin
k
develop
merck
frosstcelera
expect
approv
postmenopaus
osteoporosi
treatment
year
compound
fig
natur
product
isol
plant
mulberri
famili
artocarpu
comuni
artocarpu
altili
ic
nm
cathepsin
k
recent
relat
compound
cycloaltilisin
isol
altili
collect
micronesia
compound
potent
inhibitor
cathepsin
k
cycloaltilisin
dimer
compound
display
ic
cathepsin
k
nm
cycloaltilisin
prenyl
flavon
ic
nm
total
synthesi
cycloaltilisin
recent
report
synthet
rout
start
reaction
methyl
trihydroxyphenyl
keton
citral
afford
regiomer
benzopyran
protect
coupl
phydroxybenzaldehyd
aldol
reaction
result
intermedi
final
cycliz
afford
cycloaltilisin
fig
big
varieti
natur
product
identifi
inhibitor
cathepsin
tabl
summar
main
natur
product
report
inhibitor
cathepsin
among
first
isol
natur
product
cathepsin
inhibitor
leupeptin
leupeptin
repres
group
natur
product
includ
also
antipain
chymostatin
alphamapi
display
peptidyl
aldehyd
structur
inhibitori
activ
cathepsin
potent
irrevers
inhibitor
sever
cystein
proteas
includ
cathepsin
b
l
improv
inhibitor
deriv
synthet
compound
mirabili
afford
two
natur
product
display
activ
cathepsin
b
miraziridin
natur
product
aziridin
moieti
synthet
studi
confirm
aziridin
ring
key
inhibitori
activ
aldehyd
tokaramid
gallinamid
symplostatin
two
isomer
natur
product
isol
cyanobacteria
activ
cathepsin
b
v
l
depsipeptid
grassypeptolid
ac
also
isol
cyanobacteria
activ
cathepsin
l
cyclohexenyl
chalcon
deriv
panduratin
nicolaioidesin
c
natur
product
report
select
cathepsin
inhibitor
isol
natur
product
plant
g
brasiliensi
afford
polyprenyl
benzophenon
guttiferon
garciniaphenon
inhibit
cathepsin
b
g
terpen
compound
acid
schinol
present
mani
plant
also
identifi
inhibitor
famili
flavonoid
isol
fungi
inhibitor
cathepsin
b
l
micromolar
rang
acridon
alkaloid
isol
glutinosa
activ
recombin
human
cathepsin
v
linear
modifi
peptid
grassystatin
isol
cyanobacteria
display
high
activ
aspartyl
proteas
cathepsin
e
two
famili
natur
product
identifi
inhibitor
cathepsin
k
dipeptidyl
aldehyd
lichostatin
isol
streptomyc
cocrystal
biolog
target
prenyl
flavon
cycloaltilisin
isol
mulberri
plant
